Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center
Dear Editor, Based on studies showing in vitro antiviral activity of chloroquine (CQ) and hydroxychloroquine (HCQ) on SARS-CoV-2 (1), Belgian COVID interim guidelines rapidly (March 13th, 2020) recommended treating hospitalized patients suffering from severe COVID-19 with HCQ, 400 mg bid the first day followed by 200 mg bid for 4 additional days (for GFR > 30 ml/min). [.]
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Verlag/Hrsg.: |
Elsevier BV
|
Schlagwörter: | Public Health / Environmental and Occupational Health / Infectious Diseases |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26495617 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/230338 |